Introduction
Oncogenesis is a multi-step process that requires a long latency period between the initiating event and the appearance of the tumor. However, in a few instances, expression of a single oncogene is sucient to induce the rapid development of tumors. In rodents, polyomavirus induces a large variety of tumors, including carcinomas, lymphomas, hemangiomas and sarcomas (Gross, 1983) . The expression of the middle T oncogene (PymT), one of the polyomavirus early region genes, is sucient to transform established ®broblast cell lines, but cooperation with a second oncogene such as polyomavirus large T, is required to transform primary cell cultures (Rassoulzadegan et al., 1982) .
PymT has long been known to be sucient to induce hemangiomas in chicken (Kornbluth et al., 1986) or murine systems (Williams et al., 1988; Aguzzi et al., 1991) . The murine system has been studied in the greatest detail. Transgenic mice expressing PymT showed vascular tumors (Bautch et al., 1987) , and a retroviral construct transducing PymT transformed murine endothelial cells (EC) (Williams et al., 1988; Bussolino et al., 1991; Garlanda et al., 1994; Giraudo et al., 1996) . When injected into mice these transformed cells caused hemangiomas, mostly composed of normal host EC and few cells with PymT (Williams et al., 1988; Garlanda et al., 1994) . Though the mechanisms underlying this rare and extreme type of oncogenesis are not understood, an imbalance of urokinase-type plasminogen activator and its inhibitor is supposed to favor abnormal degradation of extracellular matrix, permitting the migration of host cells (Montesano et al., 1990; Sabapathy et al., 1997) .
The recruitment process is an example of positive tumor-host interactions where host cells acquire a tumor phenotype or participate in the formation of tumor parenchyma. Transplantation of human tumors in nu/nu mice resulted in the induction of stable transplantable tumors of murine origin Pavia, 1981, 1982; Beattie et al., 1982) . In humans, Kaposi's sarcoma, a tumor generally considered to have endothelial/mesenchymal origin, is characterized by spindle-shaped cells representing the core of the lesion and eliciting an unbalanced network of soluble mediators which is pivotal for mesenchymal cell recruitment and lesion growth (Ensoli and Sturzl, 1998) . In this context a point of interest is that these spindle cells cause vascular tumors by recruiting host elements when injected into nu/nu mice (Salahuddin et al., 1988) .
The molecular and cellular basis of cell recruitment contributing to human tumors, as well as the ontogeny of human hemangiomas and the possible involvement of a putative oncogene in their development are unknown (Drolet et al., 1999) .
In this study, we demonstrate that PymT expressed in human EC by retroviral infection caused an alteration of their phenotype. Furthermore, human EC carrying PymT induced hemangiomas by host cell recruitment in nu/nu mice and may be a useful model to study the mechanisms of cell recruitment associated to cancer and the pathogenesis of vascular tumors in humans.
Results

EC-PymT expressed active mT oncogene
Human umbilical vein EC at ®rst passage were infected with the retroviral vector pLXSN carrying PymT or with the vector alone. After selection with G418, PymT-EC and EC infected with vector alone (pLXSN-EC) were established. Figure 1 shows the PymT oncogene expression in EC-PymT at 5th and 15th passage. The Western blot analysis indicated that PymT oncogene was expressed in EC-PymT at both early and late passages. However, the amount of the transgene declined in older cultures (Figure 1a) , whereas VE-cadherin expression, an endothelial cell speci®c marker (Lampugnani et al., 1992) , was not in¯uenced by culture passages (Figure 1b) . These data indicate that culture passages speci®cally aect middle T expression.
PymT has been shown to complex with, and elevate the tyrosine kinase activity of pp60 c-src (Bolen et al., 1984; Courtneidge and Smith, 1984) . To verify the activity of PymT oncogene, cell lysate of PymT-EC at 5th and at 15th passage was immunoprecipitated by a speci®c polyclonal antibody (pAb) anti-PymT (Mullane et al., 1998) and the immunoprecipitates were incubated with [g-32 P]ATP and MG ++ to visualize the associated protein kinase activity. As expected, the immunoprecipitates contained a phosphorylated band of 56 kDa corresponding to PymT (Schahausen and Benjamin, 1981) (Figure 1c ). Some experiments have been performed by adding enolase to the immunoprecipitates, in order to quantify the kinase activity associated with PymT (Courtneidge and Smith, 1984; Kypta et al., 1990) . Figure 1c shows that this substrate is more labeled in immunoprecipitates coming from PymT-EC at early passages than in PymT-EC at late passages. The labeling of enolase in PymT-EC at 5th passage was 33-fold that in pLXSN-EC at the same passage (Pym-T-EC: 4056+345 c.p.m.; pLXSN-EC: 123+34; n=3). However, the enolase phosphorylation in PymT-immunoprecipitates from PymT-EC at 15th passage was only 22-fold as compared to pLXSN-EC (PymT-EC: 2806+217 c.p.m.; pLXSN-EC: 131+41; n=3). The 50 kDa protein is far less phosphorylated in pLXSN-EC than PymT-EC and most likely represent the heavy chain of the immuno-precipitating antibody, which is an excellent substrate for the associated pp60 src kinase activity (Sartor and Robbins, 1993) .
Characterization of PymT-EC
PymT-EC cell lines showed slight changes in morphology, but no sign of overgrowth ( Figure 2b ). They expressed von Willebrand Factor (vWF) (Figure 2a ), CD31 ( Figure 2c ) and VE-cadherin (not shown), three well-known markers of vascular EC (Garlanda and Dejana, 1997 ) with a similar pattern observed in pLXSN-EC (not shown). The expression of these markers persisted up to 12 ± 15 passages when the expression of PymT was lowered and the cells showed a senescent phenotype.
When grown in a tridimensional gel of extracellular matrix proteins, EC develop networks of cellular cords that contain a central lumen as con®rmed by transmission electron microscopy, a phenomenon named in vitro angiogenesis (Montesano et al., 1983 (Montesano et al., , 1993 Ingber and Folkman, 1989) . In our experimental conditions, control pLXSN-EC plated on a tridimensional gel of Matrigel formed branching, anastomozing cords with multicentric junctions within 18 h ( Figure  3a) . In contrast, the eect of PymT expression in EC resulted in the impairment of in vitro angiogenic eect. PymT-EC organized in large cellular nodes with cobblestone-like morphology connected by a few cord-like structures (Figure 3b) . In order to exclude that the observed behavior of PymT-EC on Matrigel was caused by a defect in adhesion machinery, we tested the adhesion of these cells on Matrigel or ®bronectin coated plates. After 30 min of incubation, the number of adherent pLXSN-EC and PymT-EC was similar (PymT-EC plated on Matrigel and on ®bronectin: 1.1+0. ; n=3).
Expression of plasminogen activator urokinase-type and plasminogen activator inhibitor-1
When PymT-EC were suspended within ®brin gel, they degraded it rapidly, suggesting that these cells had high levels of ®brinolytic activity (data not shown). In fact, the plasminogen activator urokinase-type (uPA) activity associated to cell membrane was increased in PymT transduced cells (Table 1) . To investigate the balance between uPA and plasminogen activator inhibitor-1 (PAI-1), mRNA analysis was carried out. The level of uPA transcript in PymT-EC was higher than in pLXSN-EC. When the same mRNA samples were analysed for PAI-1 expression, a marked decrease was observed as compared to control cells ( Figure 4 ). These data con®rm that PymT oncogene modi®es ®brinolytic pLXSN-EC and PymT-EC at 6th passage were cultured on Matrigel for 18 h and observed by phase-contrast microscope. pLXSN-EC form branching, anastomozing cords (a) whereas PymT-EC organize in few cords which connect large cellular cobblestone-like areas (b) (magni®cation: 1006). These experiments have been performed with similar results on six batches of PymT-EC and pLXSN-EC infected at dierent times over a period of 16 months potential of human EC as already reported in murine EC (Montesano et al., 1990) .
PymT was unable to immortalize human EC
Expression of PymT in embryonic murine EC results in immortal, established cell lines which retain the biological features of EC and grow without addition of any speci®c endothelial growth factor (Williams et al., 1988; Bussolino et al., 1991; Garlanda et al., 1994; Giraudo et al., 1996) . Long-term culture of PymT-EC never gave rise to permanent cell lines. This suggested that PymT expression was unable to immortalize human EC. To examine this in more detail, the growth properties of PymT-EC were evaluated. PymT-EC at early passages (3 ± 10) grew more rapidly than pLXSN-EC in medium containing 20% fetal calf serum (FCS). Moreover PymT-EC maintained their physiological mitogenic response to VEGF-A 165 . Like normal human EC, the proliferation of PymT-EC in presence or absence of growth factors began to decline from the 11th to the 15th passage ( Figure 5 ). To explore the potential relationship between growth arrest and senescence we looked for the presence of senescenceassociated b-galactosidase activity (SA-b-gal) (Dimri et al., 1995; Serrano et al., 1997) which has an optimal enzymatic activity at pH 6.0. The percentage of SA-bgal positive cells in PymT-EC at early passages (3 ± 10) was low (passage 3: 1.20+0.05; passage 10: 3.4+0.21; n=3), but increased from the 10th passage reaching 60 ± 70% of the cells at the 15th passage (13th passage: 32.9+3.2; 15th passage: 63.4+9.65; n=3) ( Figure 6 ).
Hemangiomas are induced by PymT-EC
Subcutaneous injection of PymT-EC at early passages into nu/nu mice caused the appearance of hemangiomas within 6 to 12 days at site of injection in all animals injected. The ability of PymT-EC at later passages to induce hemangiomas was reduced (6/10) (P=0.0287 by Fisher's exact test) ( Table 2 ). pLXSN-EC or primary human ®broblasts infected with pLXPymT were unable to induce any lesions within 8 weeks (Table 2 ). Hemangiomas were characterized by discrete blood-®lled cavities of variable size lined with a discontinuous layer of¯attened cells (Figure 7 ). Histological sections were stained with speci®c mAb anti-vWF which recognizes human and murine cells, anti-human CD31 (Parums et al., 1990) and antimouse CD31 . Figure 7b shows that hemangiomas were formed mainly by EC positive for vWF. Moreover EC which lined the large cavities of hemangiomas were recognized by a mAb anti-murine CD31 (Figure 7e ), whereas those constituting a heap near the cavities were recognized by a mAb anti-human CD31 (Figure 7c ). These results show that the PymT-EC are recruiting host EC to the tumor. With murine PymT-EC, hemangiomas continue to grow. With human PymT-EC, regression of the hemangiomas was observed over a period of 3 weeks. Figure 4 Expression of uPA, PAI-1 and GAPDH mRNA in PymT-EC at 5th passage. Northern blot analysis of total RNA (15 mg) from PymT-EC and pLXSN-EC unstimulated (7) or stimulated with 20 ng/ml of VEGF-A 165 (+) for 24 h for uPA mRNA levels (a) and PAI-1 mRNA levels (b). These experiments have been performed with similar results on six batches of PymT-EC and pLXSN-EC infected at dierent times over a period of 20 months from passage 5th to passage 10th
Discussion
In this study we demonstrate that human adult EC transduced with a retroviral vector carrying PymT exhibit an altered phenotype in vitro and induce hemangioma formation in vivo. To our knowledge, this is the ®rst evidence that PymT is able to alter human cells and induce them to cause tumors in immunode®cient mice. The eect of PymT seems to be speci®c for EC, because human primary cultures of ®broblasts infected by the same pLXSN-PymT vector are not tumorigenic. The bulk of the tumor consists of a cavity lined with a monolayer of murine EC and ®lled with blood cells. Around it, there are capillaries and vessels constituted by human EC. This hemangioma has histological features similar to murine tumors (Williams et al., 1989) , but there are many dierences between the two models. All nu/nu mice injected with PymT-EC survive and the hemangioma disappears over a period of 3 weeks. In contrast, murine EC lines carrying PymT oncogene have a dierent behavior in nu/nu or syngenic mice. Hemangiomas induced by murine cells in immunode®cient mice progress and kill the animals and they do not regress in syngenic mice (Williams et al., 1989) . This dierence could be in part explained by the dierent context where the oncogene acts in murine and in human cells. Murine EC carrying PymT result to be immortalized and transformed, but the eects of this oncogene are evident on embryonic cells, suggesting that murine EC precursors are permissive for middle T eect (Williams et al., 1988 (Williams et al., , 1989 Garlanda et al., 1994) . Here, we obtained a transient change in cell 6 PymT-EC, pLXSN-EC and human ®broblasts infected with pLXSN or pLXPymT. Mice were followed for 2 months. Tumors developed after 1 week and disappeared after 3 weeks. Over a period of 2 months pLXSN-EC and human ®broblasts did not develop any tumors and mice injected with PymT-EC did not show any tumor re-growth. The presented data have been obtained with the same batch of infected cells. A second, similar experiment has been performed with similar results by using two other batches of transduced cells biological properties and a transient tumorigenic eect by transducing adult EC. The signal transduction machinery involved in these processes requires the PymT association with pp60 c-src resulting in inappropriate activation of the kinase activity (Bolen et al., 1984; Courtneidge and Smith, 1984) . As a consequence, a variety of signal-transducing proteins are recruited and activated, including phosphatidylinositol 3-kinase (Whitman et al., 1985) , Shc (Campbell et al., 1994; Dilworth et al., 1994) , phosphatase 2A (Pallas et al., 1990) , phospholipase Cg-1 (Su et al., 1995) , GRB-2 (Campbell et al., 1994; Dilworth et al., 1994 ) and 14-3-3 proteins . Sustained increased activity of these second messenger pathways in interphase and in mitotic cells may result in inappropriate timing of phosphorylation of speci®c cellular substrates of the cell cycle and thus promote uncontrolled cell growth (Kaech et al., 1991) . In human cells PymT oncogene can be expressed and activate pp60 c-src , but is devoid of transforming properties (Schahausen et al., 1987) . In our experimental conditions, we demonstrate that PymT is expressed in human EC as ) were injected subcutaneously in nu/nu mice. After 1 week, mice were sacri®ced and paran sections of hemangiomas were analysed. (a) The hematoxylin-stained preparation shows a solitary hemangioma presenting a small blood ®lled sac (magni®cation 406). (b) The section was stained with a pAb anti-vWF which recognizes the human and murine antigen. The pAb labels endothelial cells lining the hemangioma cavity (black arrow) as well as those present in the surrounding tissue (red arrow) (1006). (c) The section was stained with mAb anti-human CD31. The area near the vascular cavity has a large number of CD31 positive EC clusters (arrows) (1006). (b) The section was stained with mAb anti-murine CD31 which labels endothelial cells lined the hemangioma cavity (arrow) (magni®cation 1006). (d) and (f) As negative control, the two sections are respectively stained with secondary antibodies biotin-conjugated rabbit-anti mouse IgG and goat anti-rat IgG (magni®cation 1006) functional protein able to activate pp60 c-src . The oncogene oers a proliferative advantage to infected cells, which is only transient and is abolished when the cells which have been cultured for 15 passages became senescent and the amount of oncogene expressed and the activity of associated pp60 c-src lowered. These changes suggest a possible relationship between the dierent levels of PymT and of pp60 c-src activity and the dierences in the proliferative response of EC. In contrast, murine EC lines carrying mT and established by embryonic tissues have an increased and permanent activation of signaling pathways triggered by mT, including phosphatidylinositol 3-kinase (Dong et al., 1996) .
The in vitro transient eects of PymT on human EC support our in vivo results characterized by the disappearance of hemangioma in nu/nu mice and the reduced tumorigenic eect of PymT-EC at later passages with a reduced growth rate. Similarly, mitomycin-C treated murine endothelioma cells, which are unable to proliferate and have a short lifespan, still induced the formation of hemangiomas that regressed after approximately 3 weeks (Williams et al., 1989) . Murine EC carrying mT oncogene are highly immunogenic Biancone et al., 1999) . Therefore, we cannot exclude that the PymT-ECinduced hemangiomas can be rejected by the residual immunological response of nu/nu mice rather than a spontaneous regression due to the intrinsic features of the injected cells. However, this hypothesis is not supported by the murine model. Hemangiomas induced by murine EC carrying PymT do not regress in nu/nu mice Williams et al., 1989) , suggesting that the dierent in vivo behavior of human and murine PymT-EC is not obligatorily the result of a dierent immunological response in the two models, but re¯ects dierent molecular mechanisms of PymT oncogene in the two cell types. In the light of our results, it is intriguing to speculate that PymT oncogene does not aect the cell cycle of human EC, but modi®es transiently their phenotype, which favors the appearance of vascular transient lesions by host cell recruitment. This altered phenotype includes (1) the unbalance of ®brinolytic system; and (2) the reduced ability to dierentiate into mature capillary, as suggested by the observation that PymT-EC form few capillary-like structures when plated on Matrigel. It should be also possible for the induction of autocrine loops involving soluble mediators as already reported in mice (Montesano et al., 1990; Taraboletti et al., 1993; Ghigo et al., 1995; Muhlner et al., 1999) .
This phenomenon is reminiscent of Kaposi's sarcoma, a multifocal proliferative disease of vascular origin. Early lesions are in®ltrated by leukocytes, producing a variety of in¯ammatory cytokines, (Ensoli and Sturzl, 1998) , that induce normal cells to acquire the Kaposi's sarcoma phenotype associated with HIV infection (Fiorelli et al., 1995) . These cytokines can also stimulate Kaposi's sarcoma cells themselves to produce other soluble mediators, including angiogenic factors. These molecules dictate the progression of the lesion by autocrine and paracrine mechanisms, regulating cell recruitment and growth, with consequent angiogenesis and lesion formation (Ensoli and Sturzl, 1998) . In some cases, Kaposi's sarcoma can regress spontaneously (Levy and Ziegler, 1983; Trattner et al., 1993) , but in later stages of development often associated to HIV-1 infection, a cell clone may assume neoplastic features, subsequent to genotypic alterations, causing the hyperplastic lesions of Kaposi's sarcoma to transform into real sarcomas (Lunardi-Iskandar et al., 1995; Albini et al., 1997) . A putative candidate for this transformation is human herpesvirus-8 (Flore et al., 1998) .
Furthermore, it is also relevant to underline that a common feature of human hemangiomas is a rapid proliferative phase followed by spontaneous involution (Drolet et al., 1999) . Indeed the described model could be a useful tool to study involuting hemangiomas.
It has been recently reported for the ®rst time, the minimum number of de®ned genetic alterations unable to transform primary cultures of human epithelial and ®broblasts cells. They include the ectopic expression of the telomerase catalytic subunit in combination with H-Ras and simian virus 40 large T oncogene (Hahn et al., 1999) . Therefore, in contrast to murine EC model where PymT oncogene transform in a single step way (Aguzzi et al., 1991; Williams et al., 1988) , we can hypothesize that an unidenti®ed human oncogene sharing similar features to PymT could play a role as co-factor in the human vascular oncogenesis. This hypothesis could open new perspectives in the pathogenesis of human vascular tumors and urges to identify the sequence of molecular alterations leading to vascular tumors.
Materials and methods
Cells
Human EC were extracted from umbilical cord veins growth and characterized as previously described (Bussolino et al., 1992) . Human ®broblasts were obtained from human skin of patients submitted to dermatological surgery, digested for 1 h at 378C in DMEM (Sigma) containing 0.1% trypsin (Gibco) and 0.1% collagenase (Boehringer). After two washes with DMEM containing 10% FCS (Gibco), cell suspension was plated in 100 mm diameter plastic dishes and grown until the con¯uence. Fibroblasts were characterized for the expression of vimentin, TE7 antigen, collagen I and collagen II, and for the absence of cytocheratin, desmin, vWF, CD45 and smooth muscle actin.
Retroviral-mediated gene transfer
Polyoma mT oncogene was subcloned in XbaI-Xho site of the expression vector pLXSN under control of LTR promoter. Amphotropic cell line PA317 was transfected with pLXSN and pLXSN-PymT to producing retroviral supernatant with high viral titer. The virus-containing medium was collected, ®ltered (0.45 mm ®lter, Millipore) and supplemented with 4 mg/ml polybrene (Sigma). EC or human ®broblasts, at I passage, were plated in 100 mm tissue culture dishes in M199 20% FCS and, for infections, the culture medium was replaced by the appropriate viral supernatant. The target cells were incubated for 5 h at 378C and 5% CO 2 and then the supernatant was replaced by 10 ml of M199 20% FCS. After 48 h, infected cells were placed under selection in G418 (Gibco) (500 ng/ml) for 1 week.
Immunofluorescence studies
PymT-EC and pLXSN-EC were grown on coverslips coated with collagen I (Sigma), incubated for 24 h in medium M199 containing 20% FCS, ®xed at room temperature for 5 min with paraformaldehyde (3%) solution, pH 7.6, containing 2% sucrose and then permeabilized (3 min at 488C) by Triton X-100 buer (20 mM HEPES, 300 mM sucrose, 50 mM NaCl, 3 mM MgCl 2 , 0.5% Triton X-100, pH 7.4) (Bussolino et al., 1987) . The coverslips were washed twice with phosphate buered saline (PBS), incubated with 10% goat serum for 10 min and then incubated 1 h at 378C with dierent mAbs: anti-vWF (diluted 1 : 10) (Boehringer), anti-human CD31 (diluted 1 : 50) (Dako), anti-VE-cadherin (diluted 1 : 50) (Lampugnani et al., 1992) . The coverslips were washed three times in PBS, incubated 1 h in¯uorescent isothiocyanate (FITC) conjugated goat anti-mouse (Sigma), washed three times in PBS and mounted in PBS-glycerol (1 : 1, v/v). Coverslips were observed by an Olympus (BX-60) microscope equipped for epi¯uorescence.
Western blot analysis and immunoprecipitation experiment
The presence of PymT and its functional activity was detected by Western blot and by an in vitro kinase assay, respectively. Total proteins (15 mg) from con¯uent cells were separated by sodiumdodecyl sulphate polyacrilammide gel electrophoresis (SDS ± PAGE) (8%), immunoblotted with mouse mAb (PM116 (1 : 100) which recognizes PymT (Holman et al., 1994) , and visualized by ECL system (PharmaciaAmersham-Biotech). For immunoprecipitation and in vitro kinase assay, con¯uent cells were washed three times with PBS containing 1 mM Na ortho-vanadate and lysed at 48C in a 25 mM HEPES buer pH 7.6, containing 150 mM NaCl, 1% NP-40, and protease and phosphates inhibitors (pepstatin, 50 mg/ml; leupeptin, 50 mg/ml; aprotinin, 10 mg/ml; 2 mM PMSF; soybean trypsin inhibitor, 500 mg/ml; ZnCl 2 , 100 mM; Na ortho-vanadate, 1 mM). After centrifugation (20 min, 10 000 g), supernatants were pre-cleared by incubation for 1 h with Protein A-Sepharose (Sigma). Samples (700 mg of proteins) were incubated with 5 ml of rabbit antiserum 45-1 which recognizes PymT in the aminoacid residues 280 ± 300 (provided by Dr B Schahausen) for 1 h and immune complexes were recovered on Protein ASepharose. Beads were washed four times with lysis buer, twice with the same buer without NP-40 and once with trisbuered saline. The in vitro kinase assay was performed in 20 mM Tris-HCl buer (pH 7.2) containing 10 mM MgCl 2 , 10 mCi [g 32 P]ATP (4000 Ci/mmole, Pharmacia-AmershamBiotech), at room temperature for 10 min. In some experiments, acid inactivated rabbit enolase (Sigma) (2.5 mg per assay) was added as substrate (Kypta et al., 1990) . Proteins were separated by SDS ± PAGE (8%), and the gel was exposed to X-ray ®lms for 24 h. The incorporation of label into enolase was assayed by counting the excised bands.
RNA extraction and Northern analysis
Total cellular RNA was isolated by RNAzol (Tel-Test Inc.) according to manufacturer's instruction by PymT-EC and pLXSN-EC. Equal amounts of total RNA (15 mg/lane) were electrophoresed in 1% agarose gels containing 6.3% formaldehyde in 3-morpholino-propanesulfonic acid buer (Sigma) and blotted on a Nylon Duralon-UV membrane (Stratagene). Hybridization was carried out overnight at 428C with a-32 P-dCTP-labeled (3000 Ci/mmol, Amersham) human uPA probe (a 1.5 Kb PstI-PstI fragment of uPA), human PAI-1 probe (a 3.2 Kb BglI-EcoRI fragment of PAI-1), and glyceraldehyde phosphate dehydrogenase (GAPDH) probe (a 1.2 Kb PstI-PstI fragment).
In vitro matrigel and fibrin gel assays Matrigel (Collaborative Biomedical Products) (0.4 ml) was added to each well of a 24-well plate and incubated at 378C to allow gel formation. PymT-EC and pLXSN-EC at 80 ± 90% con¯uence were trypsinized, washed twice with PBS, plated on Matrigel at 4 ± 5610 4 cell/well, incubated in 5% CO 2 at 378C for 18 h and then photographed.
Fibrin gel was prepared dissolving bovine ®brinogen (Sigma) immediately before the use in calcium and magnesium free DMEM (Sigma) to obtain a ®nal protein concentration of 2.5 mg/ml and ®ltered through a 0.45 mm Millipore ®lter. Bovine thrombin (Sigma), at the concentration of 25 U/ml (Sigma), was added 1/10 (v/v) to the ®brinogen. The mixture was then immediately transferred into 48-well plates and allowed to gel for 2 min before adding 5610 4 PymT-EC or pLXSN-EC. Fresh complete medium (M199 supplemented with 20% FCS) was added to the wells. The ®brin gel cultures were subsequently incubated at 378C for 1 week. The culture medium was renewed every 2 ± 3 days (Montesano et al., 1990) .
Cell growth assay
Cells (5610 3 /well) were seeded in 24-well plates and allowed to attach for 16 h in M199 containing 20% FCS. Then, fresh medium with or without 20 ng/ml of VEGF-A 165 (R&D) supplemented with 20% FCS was added. Cells were ®xed in 2.5% glutaraldehyde, stained with 0.1% crystal violet in 20% methanol, and solubilized in 10% acetic acid (Bussolino et al., 1992) . Cell growth was evaluated by measuring absorbance at 590 nm in a plate reader (Perkin-Elmer). A calibration curve was set up with known numbers of PymT-EC or pLXSN-EC and a linear correlation between absorbance and cell counts was established up to 3610 5 cells.
uPA activity assay
To measure uPA activity released in the medium and associated to cell surface, PymT-EC or pLXSN-EC were grown at con¯uence on 48-well plates, washed and incubated for 36 h in M199 without phenol red, supplemented with 20% FCS. uPA activity present in the medium was measured by an indirect assay based on the generation of plasmin from plasminogen. Fifty ml of ®ltered conditionated medium in 50 ml of assay buer [50 mM Tris with 0.1% polyethilenglicole 8000, 6 mM 6-aminohexanoic acid, and 0.1 mg/ml bovine plasminogen (American Diagnostica Inc.) pH 7.4] were incubated for 15 min at room temperature with 0.125 mmoles of H-D-norleucyl-hexahydrotyrosyl-lysine-p-nitroanilide diacetate salt (American Diagnostica Inc.), a speci®c chromogenic substrate of plasmin. The adsorbance was read at 404 nm in a plate reader (Perkin Elmer). To measure cell associated uPA activity, 50 ml of assay buer and 50 ml of chromogenic substrate were added. After 15 min at room temperature the supernatants was recovered and adsorbance was read as described before. A calibration curve was set up using an urokinase activity standard (American Diagnostica Inc.).
Adhesion assay
Following coating of 96-well plates with Matrigel or ®bronectin (Sigma) (both at 10 mg/ml) and saturation with PBS containing 3% bovine serum albumin (Sigma) for 2 h at 378C, 2610 4 cells in 100 ml of growth medium were plated in triplicate. After incubation for 60 min at 378C, wells were washed in PBS, ®xed in 2.5% glutaraldehyde (100 ml/well) for 30 min and stained with 0.1% crystal violet and processed as described before.
Injection in nu/nu mice and immunohistochemistry
PymT-EC, pLXSN-EC and human ®broblasts infected with pLX-PymT were dispersed with trypsin-EDTA, washed twice in M199 supplemented with 20% FCS, and resuspended in PBS. Three week-old nu/nu mice (Charles River Italia) were inoculated subcutaneously with 2610 6 cells. Mice were monitored daily, and size of the lesion was measured with calibre. At sacri®ce, lesions were removed, ®xed in 4% buered formaline and included in paran. Tissue sections (7 mm) were deparanized, rehydrated and incubated for 10 min with 3% H 2 O 2 in water to block endogenous peroxidase. Then a preincubation (30 min at room temperature) with normal non-immune serum (1 : 50) was followed by incubation overnight with primary mAbs anti-human CD31 (1 : 30) (Dako) and anti-murine CD31 , and pAB anti-vWF (1 : 100) (Dako). After three washes the samples were incubated respectively, with biotinylated rabbit anti-mouse immunoglobulins (Dako), goat anti-rat immunoglobulins (Sigma) and goat anti-rabbit immunoglobulins (Dako), and then with streptABC complex/horseradish peroxidase (Dako). Tissue sections were washed and developed with 3,3-diaminobenzidine tetrahydrochloride, and stained with hematoxylin.
Senescence-associated b-galactosidase
PymT-EC and pLXSN-ECs were washed once with PBS (pH 7.2), ®xed with 3% formaldehyde, washed in PBS and incubated at 378C in the dark with fresh senescenceassociated b-Gal stain solution (1 mg of 5-bromo-4-chloro-3-indolyl b-D-galactosidase dissolved in 1 ml PBS pH 6.0, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 ) (Dimri et al., 1995) . Staining was evident in 2 ± 4 h and reached the maximum after 12 ± 16 h.
